OBJECTIVE:The bioassay and HPLC methods were established and compared for the determination of levofloxacin(Lev) in human plasma.METHOD:In bioassay,medium Ⅱ and staphylococcus aureus were used.The HPLC method was chromatographed with a mobile phase of methanol-0.02mol/L potassium dihydrogen phosphate solution (3∶7)，the sample was treated by adding 30% trichloroacetic acid to precipitate protein,and detected at 276mm.RESULTS:The average recovery of bioassay was within 95.90%～106.68%,the within-day and day-to-day precisions were below 6%.The average recovery of HPLC was within 97.24%～101.70%,the within day and day-to-day precisions were blow 5%.Lev tablets were given to 6 patients in two ways.Drug concentrations in plasma were determined by bioassay and HPLC assay,respectively,with no significant difference (P＞0.05).CONCLUSION:The bioassay was simple,cheap,time saving,and reliable.The HPLC method wsa rapid,sensitive,accurate.The two methods may be selected to use in actual conditions.

OBJECTIVE: To explore the therapeutic window concentration of tacrolimus(FK506) suitable for Chinese renal transplant recipients. METHODS: The whole blood valley concentration level in 56 renal transplant recipients 12h after oral administration with FK506 was determined by MEIA (Microparticle Enzyme Immunization). The rejections and the renal toxic reaction were observed as well. RESULTS: The recommended therapeutic window concentration of FK506 for Chinese renal transplant recipients were the following: 9～14?g/L during the first month; 8～12?g/L during the second to the third month; 6～10?g/L during the fourth to the sixth month; 4～6?g/L during the seventh to the twelfth month. CONCLUSION: FK506 has a satisfactory immune suppression effect while reducing incidences of rejections and renal toxic reactions if used within the above therapeutic window concentration.

OBJECTIVE:To study the therapeutic window of peak blood concentration at different time in domestic renal transplant recipients2h after administration with cyclosporine A(CsA).METHODS:The valley bottom levels(C 0 )and the peak levels(C 2 )were determined simultaneously by fluorescence polarization immunoassay(FPIA)in92patients2h after oral administration with CsA,the rejection and the hepatic and renal drug toxicities were observed.RESULTS:The recommended therapeutic window concentration of CsA(C 2 )in Chinese renal transplant recipients was1000～1300?g/L within the first month,950～1250?g/L within the second to third month,900～1100?g/L within the fourth to sixth month,750～1000?g/L within the seventh to twelfth month,600～800?g/L from the twelfth month after renal transplantation.CONCLUSION:Within the above therapeutic window concentration range,CsA is of ideal immuno-suppressive action meanwhile it can less rejection and minimize the hepatic and renal drug toxicities.

0.05), respectively; the costs were 640.50yuan and 1 151.21yuan, respectively; the cost-effectiveness ratios were 7.01 and 12.28, respectively; the incremental cost-effectiveness ratio of Group B versus Group A was 220.1. CONCLUSION: The sequential therapy of levofloxacin is preferable in the treatment of lower respiratory infection.

0.05),the toxi?cation rate of the low dose group was lower than that of the routine group(P0.05),the effective concentration of the low dose digoxin group was significantly lower than the routine group(P